Biomarkers in Substance Use Disorders
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
The prevention and treatment of substance use disorders (SUDs), including addiction, would benefit from having better biomarkers for the classification of patients into categories that are reproducible and have predictive validity. Direct measurement of drugs or their metabolites in various body fluids constitutes a clinically valuable biomarker but one that can only be used to corroborate acute or relatively recent drug use. Thus, there is an urgent need for biomarkers that reflect chronic drug exposure as well as biomarkers that predict or correlate with disease trajectories and treatment responses. Advances in tools and technologies to investigate genetics, epigenetics and epitranscriptomics, and human brain function and neurochemistry (brain imaging tools including EEG) offer unprecedented opportunities for the development of such biomarkers. Progress in this area will not only enhance our ability to screen and treat patients with SUDs but also accelerate research on the neurobiological processes that underlie SUDs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Koob, G. F., & Volkow, N. D. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.110 · Cited by 5,340
Self-citationThe Neural Basis of Addiction: A Pathology of Motivation and Choice
Kalivas, P. W., & Volkow, N. D. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1403 · Cited by 2,757
Self-citationAddiction, a disease of compulsion and drive: involvement of the orbitofrontal cortex
Volkow, N. D. (2000) · Cerebral Cortex · doi:10.1093/cercor/10.3.318 · Cited by 1,240
Self-citationNucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement
Dalley, J. W., Fryer, T. D., Brichard, L., Robinson, E. S. J., Theobald, D. E. H., Lääne, K., Peña, Y., Murphy, E. R., Shah, Y., Probst, K., et al. (2007) · Science · doi:10.1126/science.1137073 · Cited by 1,188
Imaging dopamine's role in drug abuse and addiction
Volkow, N. D., Fowler, J. S., Wang, G. J., Baler, R., & Telang, F. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.05.022 · Cited by 988
Self-citationAddiction: Beyond dopamine reward circuitry
Volkow, N. D., Wang, G.-J., Fowler, J. S., Tomasi, D., & Telang, F. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1010654108 · Cited by 959
Self-citationCell type-specific loss of BDNF signaling mimics optogenetic control of cocaine reward
Lobo, M. K., Covington, H. E., Chaudhury, D., Friedman, A. K., Sun, H., Damez-Werno, D., Dietz, D. M., Zaman, S., Koo, J. W., Kennedy, P. J., et al. (2010) · Science · doi:10.1126/science.1188472 · Cited by 880
Neural mechanisms of genetic risk for impulsivity and violence in humans
Meyer-Lindenberg, A., Buckholtz, J. W., Kolachana, B., R. Hariri, A., Pezawas, L., Blasi, G., Wabnitz, A., Honea, R., Verchinski, B., Callicott, J. H., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511311103 · Cited by 876
Edenberg, H. J. (2007) · Europe PMC (PubMed Central) · Cited by 767
Social dominance in monkeys: dopamine D2 receptors and cocaine self-administration
Morgan, D., Grant, K. A., Gage, H. D., Mach, R. H., Kaplan, J. R., Prioleau, O., Nader, S. H., Buchheimer, N., Ehrenkaufer, R. L., & Nader, M. A. (2002) · Nature Neuroscience · doi:10.1038/nn798 · Cited by 674
Research works printed but not linked: 1
- Edenberg H. J., 2007, Alcohol Res. Health, 30, 5
Cited by
Candidate biomarkers in psychiatric disorders: state of the field
Abi‐Dargham, A., Moeller, S. J., Ali, F., DeLorenzo, C., Domschke, K., Horga, G., Jutla, A., Kotov, R., Paulus, M. P., Rubio, J. M., et al. (2023) · World Psychiatry · doi:10.1002/wps.21078 · Cited by 372
Neuroscience of Addiction: Relevance to Prevention and Treatment
Volkow, N. D., & Boyle, M. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17101174 · Cited by 322
Self-citationSubstance use and addictive disorders in DSM-5 and ICD 10 and the draft ICD 11
Saunders, J. B. (2017) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000332 · Cited by 173
Resting‐state functional connectivity and nicotine addiction: prospects for biomarker development
Fedota, J. R., & Stein, E. A. (2015) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12882 · Cited by 164
A neuromarker for drug and food craving distinguishes drug users from non-users
Koban, L., Wager, T. D., & Kober, H. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01228-w · Cited by 166
Applications of machine learning in addiction studies: A systematic review
Mak, K. K., Lee, K., & Park, C. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.03.001 · Cited by 163
Central and Peripheral Biomarkers of Stress Response for Addiction Risk and Relapse Vulnerability
Milivojevic, V., & Sinha, R. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.12.010 · Cited by 115
Ahn, W., & Vassileva, J. (2016) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.02.008 · Cited by 129
Brain ethanol metabolism by astrocytic ALDH2 drives the behavioural effects of ethanol intoxication
Jin, S., Cao, Q., Yang, F., Zhu, H., Xu, S., Chen, Q., Wang, Z., Lin, Y., Cinar, R., Pawlosky, R. J., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00357-z · Cited by 119
Self-citationAn Overview of the Epigenetic Modifications in the Brain under Normal and Pathological Conditions
Lossi, L., Castagna, C., & Merighi, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073881 · Cited by 112
“Other functional alterations disturb neurotransmitter systems, particularly the decline in dopamine and acetylcholine levels [156], and functional connectivity patterns within the brain’s networks, altering information processing and integration [157].”
BackgroundCognitive Function as a Transdiagnostic Treatment Target in Stimulant Use Disorders
Sofuoglu, M., DeVito, E. E., Waters, A. J., & Carroll, K. M. (2016) · Journal of Dual Diagnosis · doi:10.1080/15504263.2016.1146383 · Cited by 109
Emerging Role of Epigenetic Mechanisms in Alcohol Addiction
Berkel, T. D. M., & Pandey, S. C. (2017) · Alcoholism: Clinical and Experimental Research · doi:10.1111/acer.13338 · Cited by 101
Ahn, W.-Y., Ramesh, D., Moeller, F. G., & Vassileva, J. (2016) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2016.00034 · Cited by 90
“Unlike conventional univariate methods, which compare healthy and psychiatric groups on each measure at a time, machine-learning (supervised learning) methods select multivariate predictive patterns of data in a way that optimizes prediction accuracy in new samples (29–31).”
BackgroundMethodSampedro‐Piquero, P., de Guevara‐Miranda, D. L., Pavón, F. J., Serrano, A., Suárez, J., de Fonseca, F. R., Santín, L. J., & Castilla‐Ortega, E. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.11.015 · Cited by 88
Gut microbiota dysbiosis: The potential mechanisms by which alcohol disrupts gut and brain functions
Chen, G., Shi, F., Yin, W., Guo, Y., Liu, A., Shuai, J., & Sun, J. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.916765 · Cited by 99
“Previous studies report that alcohol does not bind to specific targets or receptors (Volkow et al., 2015; Jin et al., 2021).”
BackgroundA methylation study of long-term depression risk
Clark, S. L., Hattab, M. W., Chan, R. F., Shabalin, A. A., Han, L. K. M., Zhao, M., Smit, J. H., Jansen, R., Milaneschi, Y., Xie, L. Y., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0516-z · Cited by 82
W. Adams, Z., McClure, E. A., Gray, K. M., Danielson, C. K., Treiber, F. A., & Ruggiero, K. J. (2017) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.10.019 · Cited by 77
“Several biological (i.e., genetic, physiological, endocrine, neural) markers of risk, resilience, and treatment response have been identified recently in relation to psychiatric disorders (Schmidt et al., 2011; Singh and Rose, 2009; Volkow et al., 2015).”
Machine‐learning prediction of adolescent alcohol use: a cross‐study, cross‐cultural validation
Afzali, M. H., Sunderland, M., Stewart, S. H., Mâsse, B. R., Séguin, J. R., Newton, N. C., Teesson, M., & Conrod, P. (2018) · Addiction · doi:10.1111/add.14504 · Cited by 89
“Guidelines from the National Institute on Drug Abuse (NIDA) highlight machine-learning as ‘the most promising approach to identify predictive markers for psychiatric disorders and classify psychiatric populations with high-dimensional data’ [25].”
BackgroundPresynaptic G Protein-Coupled Receptors: Gatekeepers of Addiction?
Johnson, K. A., & Lovinger, D. M. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00264 · Cited by 71
“The focus is on recent evidence from laboratory animal models (and some evidence in humans) implicating these receptors in the acute and chronic effects of numerous abused drugs, as well as in the control of drug seeking and taking.”
BackgroundUsing Metabolomics to Investigate Biomarkers of Drug Addiction
Ghanbari, R., & Sumner, S. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.12.005 · Cited by 65
“Nuclear magnetic resonance spectroscopy (NMR): a spectroscopic method that uses radio frequency pulses, and magnetic properties of certain atomic phase of addiction [6].”
BackgroundBrain-derived neurotrophic factor in substance use disorders: A systematic review and meta-analysis
Ornell, F. R., Hansen, F., Schuch, F. B., Rebelatto, F. P., Tavares, A. L. J., Scherer, J. N., Valério, A. G., Pechansky, F., Kessler, F. H. P., & DIEMEN, L. V. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.08.036 · Cited by 64
Houston, R. J., & Schlienz, N. J. (2017) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2017.09.006 · Cited by 61
“Thus, a growing literature maintains that alterations in reward processing and cognitive control processes attributed to SUDs represent logical targets for interventions (20–28).”
BackgroundInfluentialSubthalamic low-frequency oscillations predict vulnerability to cocaine addiction
Degoulet, M., Tiran‐Cappello, A., Combrisson, E., Baunez, C., & Pelloux, Y. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2024121118 · Cited by 54
The Role of Working Memory for Cognitive Control in Anorexia Nervosa versus Substance Use Disorder
Brooks, S. J., Funk, S. G., Young, S. Y., & Schiöth, H. B. (2017) · Frontiers in Psychology · doi:10.3389/fpsyg.2017.01651 · Cited by 58
“Specifically, in terms of SUD, there is an urgent need for biomarkers that are associated with chronic addiction to be classified, but presently the dopaminergic reward system appears to be key (Volkow et al., 2015).”
BackgroundA review of the neurobiological underpinning of comorbid substance use and mood disorders
Gómez‐Coronado, N., Sethi, R., Bortolasci, C. C., Arancini, L., Berk, M., & Dodd, S. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.08.041 · Cited by 59
The future of translational research on alcohol use disorder
Ray, L. A., Grodin, E. N., Leggio, L., Bechtholt, A. J., Becker, H., Feldstein Ewing, S. W., Jentsch, J. D., King, A. C., Mason, B. J., O'Malley, S., et al. (2021) · Addiction Biology · doi:10.1111/adb.12903 · Cited by 47
“translation and reverse translation of therapeutic discoveries.(7,72,73)”
Self-citationWiers, C. E., Shumay, E., Volkow, N. D., Frieling, H., Kotsiari, A., Lindenmeyer, J., Walter, H., & Bermpohl, F. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.141 · Cited by 47
Self-citationPlasma interleukin-6 and executive function in crack cocaine-dependent women.
Levandowski, M. L., Hess, A. R. B., Grassi-Oliveira, R., & de Almeida, R. M. M. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.06.023 · Cited by 45
Yčas, J. W. (2017) · Advances in clinical chemistry · doi:10.1016/bs.acc.2017.06.002 · Cited by 48
Addiction Cue-Reactivity Initiative (ACRI) Network, Sangchooli, A., Zare-Bidoky, M., Jouzdani, A. F., Schacht, J. P., Bjork, J. M., Claus, E. D., Prisciandaro, J. J., Wilson, S. J., Wüstenberg, T., et al. (2024) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2023.5483 · Cited by 46
Worhunsky, P. D., Matuskey, D., Gallezot, J.-D., Gaiser, E. C., Nabulsi, N., Angarita, G. A., Calhoun, V. D., Malison, R. T., Potenza, M. N., & Carson, R. E. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.01.045 · Cited by 43
“Dissociating potential dopaminergic vulnerabilities to addictive disorders and dopaminergic consequences of substance use remains an important area of addictions research (Volkow et al., 2015).”
BackgroundJun, H., Webb-Morgan, M., Felner, J. K., Wisdom, J. P., Haley, S. J., Austin, S. B., Katuska, L. M., & Corliss, H. L. (2019) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2019.107619 · Cited by 45
“This indicates that SGMs may be more likely to use different substances than non-SGMs, which has implications for screening, intervention, and treatment (Magill and Ray, 2009; Volkow et al., 2015).”
BackgroundLenze, E. J., Nicol, G. E., Barbour, D. L., Kannampallil, T., Wong, A. W. K., Piccirillo, J., Drysdale, A. T., Sylvester, C. M., Haddad, R., Miller, J. P., et al. (2021) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.200042 · Cited by 43
Challenges and promises for translating computational tools into clinical practice
Ahn, W., & Busemeyer, J. R. (2016) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2016.02.001 · Cited by 49
“Thus, finding markers that are affordable yet predictive of clinical outcomes would have important practical implications [61 ].”
BackgroundRole of microRNAs in the pathophysiology of addiction
Gowen, A. M., Odegaard, K. E., Hernandez, J. B., Chand, S., Koul, S., Pendyala, G., & Yelamanchili, S. V. (2020) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1637 · Cited by 44
“…or dopaminergic pathway, is conserved throughout most drugs of abuse, including psychostimulants, and is comprised of the activation of the dopaminergic neurons in the ventral tegmental area (VTA) and substantia nigra, which affect GABAergic neurons in the striatum (N. D. Volkow & Morales, 2015).”
BackgroundThe importance of epigenetics in diagnostics and treatment of major depressive disorder
Czarny, P., Białek, K., Ziółkowska, S., Strycharz, J., Barszczewska, G., & Sliwinski, T. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11030167 · Cited by 37
Nguyen, N. P. T., Islam, S. N., Llanes, K. D., Koester, K. A., & Ling, P. M. (2024) · Addictive Behaviors · doi:10.1016/j.addbeh.2024.107971 · Cited by 39
Webber, H. E., de Dios, C., Kessler, D. A., Schmitz, J. M., Lane, S. D., & Suchting, R. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104835 · Cited by 36
Ayers-Ringler, J. R., Oliveros, A., Qiu, Y., Lindberg, D. M., Hinton, D. J., Moore, R. M., Dasari, S., & Choi, D. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00046 · Cited by 36
“Research into the neuronal mechanisms of addiction has revealed changes primarily in the dopamine (DA), gammaaminobutyric acid (GABA) and glutamate signaling pathways (Koob and Volkow, 2010; Koob, 2014; Most et al., 2014; Wang et al., 2014, 2015; Volkow et al., 2015; Didone et al., 2016).”
BackgroundWade, N. E., Bagot, K. S., Cota, C. I., Fotros, A., Squeglia, L. M., Meredith, L. R., & Jacobus, J. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119855971 · Cited by 36
“Understanding neurobiological factors that predict cannabis use onset in adolescents may focus the development of prevention and intervention efforts (Volkow et al., 2015, 2016).”
Contributions of mobile technologies to addiction research
Swendsen, J. D. (2016) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2016.18.2/jswendsen · Cited by 37
A Longitudinal Investigation of Blood Neurofilament Light Chain Levels in Chronic Cocaine Users
Bavato, F., Kexel, A.-K., Kluwe‐Schiavon, B., Maceski, A. M., Baumgartner, M. R., Seifritz, E., Kühle, J., & Quednow, B. B. (2022) · Molecular Neurobiology · doi:10.1007/s12035-023-03327-6 · Cited by 32
Development of the Highly Processed Food Withdrawal Scale for Children
Parnarouskis, L., LaFata, E. M., Lumeng, J. C., & Gearhardt, A. N. (2019) · Appetite · doi:10.1016/j.appet.2019.104553 · Cited by 31
Neuroimaging biomarkers of addiction
Ekhtiari, H., Sangchooli, A., Carmichael, O. T., Moeller, F. G., O’Donnell, P., Oquendo, M. A., Paulus, M. P., Pizzagalli, D. A., Ramey, T., Schacht, J. P., et al. (2024) · Nature Mental Health · doi:10.1038/s44220-024-00334-x · Cited by 31
“PET and SPECT studies have demonstrated that dopamine transporter and D2 dopamine receptor availability are consistently downregulated in SUDs, especially D2 receptors in the striatum whose downregulation is associated with compulsive drug use 72 .”
Hellem, T., Shi, X., Latendresse, G., & Renshaw, P. F. (2015) · Journal of the American Psychiatric Nurses Association · doi:10.1177/1078390315598606 · Cited by 32
Poolakkandy, R. R., & Menamparambath, M. M. (2020) · Electrochemical Science Advances · doi:10.1002/elsa.202000024 · Cited by 28
Perez, C. F., Reguilón, M. D., Manzanedo, C., Aguilar, M. A., Miñarro, J., & Rodríguez‐Arias, M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.01.052 · Cited by 28
“vironmental factors, characterized by a loss of control over use of the drug (Kalivas and Volkow, 2005; Koob, 2010; Koob and Volkow, 2009; Volkow et al., 2015).”
Immunotherapies for the Treatment of Drug Addiction
Hossain, M. K., Davidson, M., Kypreos, E., Feehan, J., Muir, J. A., Nurgali, K., & Apostolopoulos, V. (2022) · Vaccines · doi:10.3390/vaccines10111778 · Cited by 27
Defining Substance Use Disorders: The Need for Peripheral Biomarkers
Bough, K. J., & Pollock, J. D. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.12.009 · Cited by 27
Biomarkers of the Endocannabinoid System in Substance Use Disorders
Navarrete, F., García‐Gutiérrez, M. S., Gasparyan, A., Navarro, D., Lopez‐Picon, F. R., Morcuende, Á., Femenía, T., & Manzanares, J. (2022) · Biomolecules · doi:10.3390/biom12030396 · Cited by 28
Vines, L., Sotelo, D., Johnson, A., Dennis, E., Manza, P., Volkow, N. D., & Wang, G. (2022) · Intelligent Medicine · doi:10.1016/j.imed.2022.03.001 · Cited by 27
Self-citationChen, F., Yu, X., Shi, K., Zhang, Z., Xie, Z., Wu, H., Ma, Y., Zhou, Y. C., Chen, C. Y., Yang, J., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113685 · Cited by 27
Liu, X., Li, L., Li, J., Tang, J., Rong, J., Liu, B., & Hu, Z. (2017) · Brain and Behavior · doi:10.1002/brb3.769 · Cited by 30
Roberts, A. J., Casal, L., Huitrón‐Reséndiz, S., Thompson, T., & Tarantino, L. M. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4834-7 · Cited by 27
“Great strides have been made in understanding the neural and molecular pathways in all stages of addiction (Koob and Volkow 2010; Russo et al. 2010; Volkow et al. 2015), but studying the entire spectrum in humans is difficult due to lack of control over the environment, including previous drug…”
BackgroundZhao, K., Fonzo, G. A., Xie, H., Oathes, D. J., Keller, C. J., Carlisle, N. B., Etkin, A., Garza‐Villarreal, E. A., & Zhang, Y. (2024) · Nature Mental Health · doi:10.1038/s44220-024-00209-1 · Cited by 25
“Establishing robust and generalizable neuroimaging-based biomarkers could be helpful in advancing our understanding of the neurobiological mechanism and pathophysiology of CUD 4,5 .”
Han, D., Lee, S. H., Lee, S., & Seo, D. (2021) · Preventive Medicine · doi:10.1016/j.ypmed.2021.106418 · Cited by 25
Gowin, J. L., Ernst, M., Ball, T., May, A. C., Sloan, M. E., Tapert, S. F., & Paulus, M. P. (2019) · NeuroImage: Clinical · doi:10.1016/j.nicl.2019.101676 · Cited by 22
“Accordingly, a major research goal has been to identify patterns of brain activity that predict relapse following treatment (Volkow et al., 2015).”
InfluentialFritz, B. M., & Boehm, S. L. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.05.012 · Cited by 26
“Furthermore, a link between dopamine D2 receptor levels/function and ethanol abuse/dependence has been demonstrated in the clinical literature (Volkow et al., 1996, 2015) and in rodent models (Bice et al., 2008; McBride et al., 1993; Ng et al., 1994; Phillips et al., 1998; Thanos et al., 2001,…”
BackgroundMohammadi, S., Beh-Pajooh, A., Ahmadimanesh, M., Amini, M., Ghazi-Khansari, M., Moallem, S. A., Hosseini, R., Nourian, Y. H., & Ghahremani, M. H. (2022) · Epigenomics · doi:10.2217/epi-2022-0246 · Cited by 23
Gould, R. W., Czoty, P. W., Porrino, L. J., & Nader, M. A. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2016.285 · Cited by 25
Biosignature Discovery for Substance Use Disorders Using Statistical Learning
Baurley, J. W., McMahan, C. S., Ervin, C. M., Pardamean, B., & Bergen, A. W. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.12.008 · Cited by 21
“They are not, however readily available for the neurobiological modifications that result in the maladaptive behaviors we describe as addiction [4].”
BackgroundAnthocyanin as neuroprotector for methamphetamine-induced neurotoxicity
Primatanti, P. A., & Jawi, I. M. (2019) · International journal of health & medical sciences · doi:10.31295/ijhms.v3n1.101 · Cited by 19
“These changes are commonly found in striatum (caudate nucleus-putamen), hypothalamus, thalamus, cortex, and hippocampus (Yamada, 2008; Chen et al., 2014; Salamanca et al., 2015; Volkow et al., 2015; Heinsleigh, 2017).”
BackgroundReevaluating the brain disease model of addiction
Blithikioti, C., Fried, E. I., Albanese, E., Field, M., & Cristea, I. A. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00060-4 · Cited by 20
“2 However, this argument has been made since the inception of the BDMA, and after decades of investments with disappointing results, 9,44 the optimism seems unwarranted.”
Shi, Z., Langleben, D. D., O’Brien, C. P., Childress, A. R., & Wiers, C. E. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102806 · Cited by 18
“, 2016) and has strong potential for the identification of neural signatures of clinical diagnoses and treatment responses (Abi-Dargham and Horga, 2016; Garrison and Potenza, 2014; Orrù et al., 2012; Sundermann et al., 2014; Volkow et al., 2015; Woo et al., 2017).”
BackgroundIncreased cortisol levels are associated with low treatment retention in crack cocaine users
Ligabue, K. P., Schuch, J. B., Scherer, J. N., Ornell, F. R., Roglio, V. S., de Assunção, V. A. F., Rebelatto, F. P., Hidalgo, M. P., Pechansky, F., Kessler, F. H. P., et al. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2019.106260 · Cited by 17
Cognitive–affective factors underlying disinhibitory disorders and legal implications
Baskin-sommers, A. R., Ruiz, S. G., Sarcos, B., & Simmons, C. (2022) · Nature Reviews Psychology · doi:10.1038/s44159-022-00020-8 · Cited by 18
Scherer, J. N., Schuch, S., Ornell, F. R., Sordi, A. O., Bristot, G., Pfaffenseller, B., Kapczinski, F. P., Kessler, F. H. P., Fumagalli, F., Pechansky, F., et al. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.07.050 · Cited by 19
“Due to the difficulties associated to therapeutic strategies, Volkow et al [30] recently pointed out to the crucial need for researching biomarkers that could reflect chronic drug use, as well as predict disease trajectories, treatment adherence and prognosis.”
Leptin levels and its correlation with crack-cocaine use severity: A preliminary study
Escobar, M., Scherer, J. N., Ornell, F. R., Bristot, G., Soares, C. M., Guimarães, L. S. P., DIEMEN, L. V., & Pechansky, F. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.02.009 · Cited by 18
Blum, K., Febo, M., Badgaiyan, R. D., Braverman, E. R., Dushaj, K., Li, M., & Demetrovics, Z. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160719111346 · Cited by 15
“This dopamine release results in the feeling of reward [1, 157-168].”
BackgroundCates, H. M., Benca‐Bachman, C. E., de Guglielmo, G., Schoenrock, S. A., Shu, C., & Kallupi, M. (2019) · Genes Brain & Behavior · doi:10.1111/gbb.12577 · Cited by 15
“Substance use disorder is a chronic brain disease that is characterized by compulsive drug seeking, relapse and persistent use despite serious and harmful consequences.(1) In the past 5 years, OUD, has become a crisis in the United States.”
BackgroundCue-Elicited Brain Activity and Treatment Outcomes in Substance Use Disorders: A Meta-Analysis
Evohr, B., Wenzel, S., Chen, N., Wade, C., Ekhtiari, H., Ketron, A. C., Janes, A. C., & Gilman, J. M. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.48809 · Cited by 14
Cocaine addicted rats show reduced neural activity as revealed by manganese-enhanced MRI
Cannella, N., Cosa‐Linan, A., Takahashi, T. T., Weber‐Fahr, W., & Spanagel, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-76182-3 · Cited by 14
“3], group by time interaction [F(1,34) = 0.”
BackgroundJordan, C. J., & Andersen, S. L. (2017) · Addiction Biology · doi:10.1111/adb.12535 · Cited by 15
Manzanares, J., Sala, F., García‐Gutiérrez, M. S., & Rueda, F. N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00060-8 · Cited by 14
Butelman, E. R., Huang, Y., Cathomas, F., Gaudreault, P., Roussos, P., Russo, S. J., Goldstein, R. Z., & Alia‐Klein, N. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03119-z · Cited by 11
Basova, L., Lindsey, A., McGovern, A. M., Ellis, R. J., & Marcondes, M. C. G. (2021) · Viruses · doi:10.3390/v13040544 · Cited by 10
Serum BDNF levels increase during early drug withdrawal in alcohol and crack cocaine addiction
Ornell, F., Scherer, J. N., Schuch, J. B., Sordi, A. O., Halpern, S. C., Rebelatto, F. P., Bristot, G., Kapczinski, F., Roglio, V. S., Pechansky, F., et al. (2023) · Alcohol · doi:10.1016/j.alcohol.2023.04.001 · Cited by 9
Addictive behaviors: decades of research, but still so many questions!
Campanella, S. (2024) · Frontiers in Psychology · doi:10.3389/fpsyg.2024.1485118 · Cited by 9
Gorgich, E. A. C., Rigi, M. G., Fanaei, H., Parsaei, H., & Ghanbarzehi, A. (2024) · Substance Abuse Treatment Prevention and Policy · doi:10.1186/s13011-024-00591-0 · Cited by 9
Ngbokoli, M. L., Douton, J. E., & Carelli, R. M. (2023) · Addiction Neuroscience · doi:10.1016/j.addicn.2023.100097 · Cited by 9
A systematic review on Substance Addiction: medical diagnosis or morality flaw?
Barata, P. C., Oliveira, C., Castro, S., & Mota, A. M. (2019) · The European Journal of Psychiatry · doi:10.1016/j.ejpsy.2019.07.001 · Cited by 11
Kwon, M., Kim, H., Yang, J., Lee, Y., Hur, J. K., Lee, T., Bjork, J. M., & Ahn, W. (2023) · Substance Use & Misuse · doi:10.1080/10826084.2023.2259471 · Cited by 8
“…shrinkage and selection operator (LASSO) regression; Tibshirani, 1996) to the measures so that we could identify multivariate risk factors for SUDs associated with daily caffeinated soda intake and select features that are highly associated with caffeinated soda intake (Volkow et al., 2015).”
BackgroundMaki, K. A., Wallen, G. R., Bastiaanssen, T. F. S., Hsu, L., Valencia, M. E., Ramchandani, V. A., Schwandt, M. L., Diazgranados, N., Cryan, J. F., Momenan, R., et al. (2024) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.15346 · Cited by 8
Merritt, C. R., Smith, A. E., Khanipov, K., Golovko, G., Dineley, K. T., Anastasio, N. C., & Cunningham, K. A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1022863 · Cited by 8
“Nextgeneration sequencing (NGS) and bioinformatics analyses were utilized to identify neurobiological signatures within the mPFC transcriptome that correlate with heightened sensitivity to cocaine-associated cues (Geschwind and Konopka, 2009; Wang et al., 2009; Volkow et al., 2015).”
MethodRuiz, S. G., Brazil, I. A., & Baskin-sommers, A. R. (2023) · Scientific Reports · doi:10.1038/s41598-023-38991-0 · Cited by 8
Webber, H. E., de Dios, C., Kessler, D. A., Schmitz, J. M., Lane, S. D., & Suchting, R. (2024) · Psychophysiology · doi:10.1111/psyp.14515 · Cited by 9
Neurotransmitter system aberrations in patients with drug addiction
Wei, Z., Wu, Q., Liu, Q., & Cheng, Y. (2020) · Journal of Neural Transmission · doi:10.1007/s00702-020-02242-7 · Cited by 8
Inherent Motor Impulsivity Associates with Specific Gene Targets in the Rat Medial Prefrontal Cortex
Sholler, D. J., Merritt, C. R., Davis-Reyes, B. D., Golovko, G., Anastasio, N. C., & Cunningham, K. A. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.03.045 · Cited by 7
Multimodal Assessment of Smoking cue Reactivity During a Smoking Cue Exposure Task
Kroczek, A., Schröder, B., Rosenbaum, D., Mühleck, A., Diemer, J., Mühlberger, A., Fallgatter, A. J., Batra, A., & Ehlis, A. (2022) · Clinical EEG and Neuroscience · doi:10.1177/15500594221138273 · Cited by 6
Psychopharmacological Perspectives and Diagnosis of Substance Use Disorder
Duresso, S. W. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.99531 · Cited by 6
Serotonin neurobiology in cocaine use disorder
Cunningham, K. A., Howell, L. L., & Anastasio, N. C. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-444-64125-0.00040-2 · Cited by 7
Kirsch, D. E., Grodin, E. N., Leggio, L., McKee, S. A., Meredith, L. R., Mereish, E. H., Miranda, R., Nieto, S. J., O’Malley, S. S., Schacht, J. P., et al. (2025) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.70170 · Cited by 6
Womersley, J. S., Mpeta, B., Dimatelis, J. J., Kellaway, L. A., Stein, D. J., & Russell, V. A. (2016) · Behavioral and Brain Functions · doi:10.1186/s12993-016-0102-3 · Cited by 6
“The subsequent supraphysiological levels of dopamine are responsible for the rewarding properties of drugs and in turn influence a number of dopamine-dependent behavioural processes, which are comorbid with the development of SUDs, such as altered motivation, motor output, impulsivity and reward processing [10, 16].”
BackgroundDevelopment of New Diagnostic Techniques – Machine Learning
Sun, D. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-5562-1_10 · Cited by 5
Trifu, S. C., Țîbîrnă, A., Costea, R., & Popescu, A. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9702 · Cited by 5
“Apart from the variation in metabolic enzymes, it is believed that genes influ‐ ence other aspects of addiction such as learning or behavioral disinhibition/impulsivity (22,24).”
BackgroundCortisol as a risk biomarker to guide recovery from substance use disorders
Fitzpatrick‐Schmidt, T., & Edwards, S. (2023) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.15018 · Cited by 5
Sex differences in circulating inflammatory mediators as a function of substance use disorder
May, A. C., Burrows, K., Figueroa‐Hall, L. K., Kirlić, N., White, E. J., Smith, R. S., Ekhtiari, H., Paulus, M. P., Savitz, J. B., & Stewart, J. L. (2021) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2021.108610 · Cited by 5
“The predominant focus of existing research on a single disorder in isolation, with the exception of meta-analyses, limits generalizability given the high comorbidity among mood/ anxiety disorders and SUDs in the population (e.g., Grisanzio et al., 2018; Pinto et al., 2017; Volkow et al., 2015).”
BackgroundYan, K., Xu, S., Fang, H., Yang, H., & Su, D. (2025) · Vaccine · doi:10.1016/j.vaccine.2025.127036 · Cited by 4
Löfberg, A., Harp, N. R., Perini, I., Kämpe, R., Karlsson, H., Pietrzak, M. B., Kober, H., & Heilig, M. A. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02369-3 · Cited by 4
“Importantly, brain-based biomarkers can overcome limitations of self-reports (e.g., social desirability biases; [7]), limited self-insight among those struggling with substance use disorders [8, 9], and move the fi eld closer to personalized interventions [4].”
A Review on Recent Machine Learning Applications for Addiction Disorders
Bouhadja, A., & Bouramoul, A. (2022) · International Conference on Pattern Analysis and Intelligent Systems (PAIS) · doi:10.1109/pais56586.2022.9946888 · Cited by 6
“ML considered powerful tool also in identifying characteristics that indicate SUD [61].”
Method
Metadata
- Authors
- Volkow, N. D., Koob, G., & Baler, R.
- Affiliations
- National Institutes of Health (US)
- National Institute on Drug Abuse and ‡National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, Maryland 20892, United States
- Corresponding author
- Volkow, Nora D
- Venue
- ACS Chemical Neuroscience
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-03-18
- Volume
- 6
- Issue
- 4
- Pages
- 522-525
- ISSN
- 1948-7193 (ISSN-L)
- OpenAlex
- W2057763983
- Cited by
- 141
- References
- 41
- Citations by year
- 2026: 5 · 2025: 14 · 2024: 17 · 2023: 8 · 2022: 18 · 2021: 13 · 2020: 11 · 2019: 13 · 2018: 15 · 2017: 10 · 2016: 13 · 2015: 4
- FWCI
- 1.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- ACS Chemical Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Keywords
- substance use disorders, addiction, biomarkers, chronic drug exposure, disease trajectories, treatment response prediction, epigenetics, epitranscriptomics, neuroimaging, EEG, neurochemistry
- MeSH terms
- Animals, Humans, Biomarkers, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.